FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361817962> ?p ?o ?g. }

• W4361817962 abstract "<div>Abstract<p><b>Purpose:</b> To safely assess new drugs, cancer patients in initial cohorts of phase I oncology studies receive low drug doses. Doses are successively increased until the maximum tolerated dose (MTD) is determined. Because traditional chemotherapy is often more effective near the MTD, ethical concerns have been raised about administration of low drug doses to phase I patients. However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies.</p><p><b>Experimental Design:</b> Twenty-four consecutive trials treating 683 patients between October 1, 2004, and June 30, 2008, at MD Anderson Cancer Center were analyzed. Patients were assigned to a low-dose (≤25% MTD), medium-dose (25-75% MTD), or high-dose (≥75% MTD) group, and groups were compared for response rate, time-to-treatment failure, progression-free survival, overall survival, and toxicity. To remove negatively biasing data from the high-dose group, in a second analysis, patients treated above the MTD were excluded (high-dose group, 75-100% MTD). Of the 683 patients, 97.7% received targeted agents.</p><p><b>Results:</b> Even when excluding patients above the MTD, there was an early trend favoring the low- versus high-dose group in time-to-treatment failure, with 32.9% versus 25.2% of patients on therapy at 3 months (<i>P</i> = 0.08). In addition, the low-dose group fared at least as well as the other groups in all other outcomes, including response rate, progression-free survival, overall survival, and toxicity.</p><p><b>Conclusions:</b> These data may help alleviate concerns that patients who receive low drug doses on contemporary phase I oncology trials fare worse and suggest targeted agents may have different dose-response relationships than cytotoxic chemotherapies. Clin Cancer Res; 16(4); 1289–97</p></div>" @default.
• W4361817962 created "2023-04-05" @default.
• W4361817962 creator A5005436649 @default.
• W4361817962 creator A5009418529 @default.
• W4361817962 creator A5012517342 @default.
• W4361817962 creator A5026095888 @default.
• W4361817962 creator A5032507421 @default.
• W4361817962 creator A5036211173 @default.
• W4361817962 creator A5053481267 @default.
• W4361817962 creator A5059492624 @default.
• W4361817962 date "2023-03-31" @default.
• W4361817962 modified "2023-09-27" @default.
• W4361817962 title "Data from Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse" @default.
• W4361817962 doi "https://doi.org/10.1158/1078-0432.c.6519332.v1" @default.
• W4361817962 hasPublicationYear "2023" @default.
• W4361817962 type Work @default.
• W4361817962 citedByCount "0" @default.
• W4361817962 crossrefType "posted-content" @default.
• W4361817962 hasAuthorship W4361817962A5005436649 @default.
• W4361817962 hasAuthorship W4361817962A5009418529 @default.
• W4361817962 hasAuthorship W4361817962A5012517342 @default.
• W4361817962 hasAuthorship W4361817962A5026095888 @default.
• W4361817962 hasAuthorship W4361817962A5032507421 @default.
• W4361817962 hasAuthorship W4361817962A5036211173 @default.
• W4361817962 hasAuthorship W4361817962A5053481267 @default.
• W4361817962 hasAuthorship W4361817962A5059492624 @default.
• W4361817962 hasConcept C121608353 @default.
• W4361817962 hasConcept C126322002 @default.
• W4361817962 hasConcept C143998085 @default.
• W4361817962 hasConcept C29730261 @default.
• W4361817962 hasConcept C535046627 @default.
• W4361817962 hasConcept C71924100 @default.
• W4361817962 hasConcept C90924648 @default.
• W4361817962 hasConceptScore W4361817962C121608353 @default.
• W4361817962 hasConceptScore W4361817962C126322002 @default.
• W4361817962 hasConceptScore W4361817962C143998085 @default.
• W4361817962 hasConceptScore W4361817962C29730261 @default.
• W4361817962 hasConceptScore W4361817962C535046627 @default.
• W4361817962 hasConceptScore W4361817962C71924100 @default.
• W4361817962 hasConceptScore W4361817962C90924648 @default.
• W4361817962 hasLocation W43618179621 @default.
• W4361817962 hasOpenAccess W4361817962 @default.
• W4361817962 hasPrimaryLocation W43618179621 @default.
• W4361817962 hasRelatedWork W2004664608 @default.
• W4361817962 hasRelatedWork W2014119546 @default.
• W4361817962 hasRelatedWork W2117221775 @default.
• W4361817962 hasRelatedWork W2128222437 @default.
• W4361817962 hasRelatedWork W2142488125 @default.
• W4361817962 hasRelatedWork W2350931032 @default.
• W4361817962 hasRelatedWork W2365364931 @default.
• W4361817962 hasRelatedWork W2374149423 @default.
• W4361817962 hasRelatedWork W2418638721 @default.
• W4361817962 hasRelatedWork W2913239611 @default.
• W4361817962 isParatext "false" @default.
• W4361817962 isRetracted "false" @default.
• W4361817962 workType "article" @default.